Repeatability of hypoxia PET imaging using $[^{18}F]$HX4 in lung and head and neck cancer patients: a prospective multicenter trial

Catharina M. L. Zegers, Wouter van Elmpt, Katrin Szardenings, Hartmuth Kolb, Alan Waxman, Rathan M. Subramaniam, Dae Hyuk Moon, Jacqueline C. Brunetti, Shyam M. Srinivas, Philippe Lambin, David Chien

Abstract

Purpose Hypoxia is an important factor influencing tumor progression and treatment efficacy. The aim of this study was to investigate the repeatability of hypoxia PET imaging with $[^{18}F]$HX4 in patients with head and neck and lung cancer.

Methods Nine patients with lung cancer and ten with head and neck cancer were included in the analysis (NCT01075399). Two sequential pretreatment $[^{18}F]$HX4 PET/CT scans were acquired within 1 week. The maximal and mean standardized uptake values (SUV$_{\text{max}}$ and SUV$_{\text{mean}}$) were defined and the tumor-to-background ratios (TBR) were calculated. In addition, hypoxic volumes were determined as the volume of the tumor with a TBR > 1.2 (HV$_{1.2}$). Bland Altman analysis of the uptake parameters was performed and coefficients of repeatability were calculated. To evaluate the spatial repeatability of the uptake, the PET/CT images were registered and a voxel-wise comparison of the uptake was performed, providing a correlation coefficient.

Results All parameters of $[^{18}F]$HX4 uptake were significantly correlated between scans: SUV$_{\text{max}}$ ($r=0.958$, $p<0.001$), SUV$_{\text{mean}}$ ($r=0.946$, $p<0.001$), TBR$_{\text{max}}$ ($r=0.962$, $p<0.001$) and HV$_{1.2}$ ($r=0.995$, $p<0.001$). The relative coefficients of repeatability were 15% (SUV$_{\text{mean}}$), 17% (SUV$_{\text{max}}$) and 17% (TBR$_{\text{max}}$). Voxel-wise analysis of the spatial uptake pattern within the tumors provided an average correlation of 0.65±0.14.

Conclusion Repeated hypoxia PET scans with $[^{18}F]$HX4 provide reproducible and spatially stable results in patients with head and neck cancer and patients with lung cancer. $[^{18}F]$HX4 PET imaging can be used to assess the hypoxic status of tumors and has the potential to aid hypoxia-targeted treatments.

Keywords PET imaging · HX4 · Hypoxia · Head and neck cancer · Lung cancer

Electronic supplementary material The online version of this article (doi:10.1007/s00259-015-3100-z) contains supplementary material, which is available to authorized users.

Catharina M. L. Zegers
Karen.zegers@maastro.nl

1 Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands

2 Threshold Pharmaceuticals, 170 Harbor Way, South San Francisco, CA 94080, USA

3 Siemens Molecular Imaging Biomarker Research, Siemens Medical Solutions USA, Inc., 6100 Bristol Parkway, Culver City, CA, USA

4 Cedars-Sinai Medical Center, Los Angeles, CA, USA

5 Boston University School of Medicine, Boston, MA, USA

6 Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

7 Holy Name Medical Center, Teaneck, NJ, USA

8 Department of Nuclear Medicine, Imaging Institute, Cleveland Clinic, Cleveland, OH 44195, USA

9 Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiologic Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA
Introduction

[18F]HX4 is a new 2-nitroimidazole PET imaging agent for hypoxia, in which structure–activity relationships have been used to optimize pharmacokinetic and clearance properties [1, 2]. Tumor hypoxia is a condition in which insufficiently vascularized tumor cells deprived of oxygen not only become more aggressive and malignant, but also more resistant to treatment by radiation and chemotherapy [3–5]. The presence of hypoxia is therefore generally considered a poor prognostic disease marker in cancer patients [6]. However, it is difficult to measure oxygen levels reproducibly and noninvasively in a highly heterogeneous tumor environment. Reliable diagnostic methods to detect and quantify tumor hypoxia are therefore needed. It has been hypothesized and currently being investigated that inclusion of hypoxic cell sensitizers during treatment, i.e., the delivery of higher radiotherapy doses to hypoxic regions [7] or the use of hypoxia-targeting therapy [8–11], might improve the outcome in patients with hypoxic tumors [12]. [18F]HX4 has the potential to serve as a clinically useful diagnostic tool to aid the use of hypoxia-targeting therapies in those patients who will most likely benefit from them [13, 14].

This pilot phase 2 study was primarily designed as a test-retest study to investigate the repeatability of [18F]HX4 as a noninvasive PET imaging marker for detection of tumor hypoxic regions. Here we present the results in patients with lung cancer and patients with head and neck (H&N) cancer.

Materials and methods

Patients

This multicenter study (NCT01075399) was conducted in accordance with the ethical principles of Good Clinical Practice, according to the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Both the FDA and the institutional review boards of the participating institutions approved the study protocol and the informed consent form. All participants reviewed and signed the informed consent form before study entry. [18F]HX4 PET/CT images were acquired in 19 patients, 9 with lung cancer and 10 with H&N cancer. The patients underwent two sequential pretreatment [18F]HX4 PET/CT scans within 1 week to assess repeatability. Patient characteristics are presented in Table 1.

Radiochemistry

[18F]HX4 (flortanidazole, 3-[18F]fluoro-2-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-propan-1-ol) was prepared by Siemens Molecular Imaging (Culver City, CA) or a Siemens PETNET qualified manufacturing site and delivered to each site on the day of injection. The radiosynthesis has been described previously [15]. Briefly, the precursor (Siemens Molecular Imaging Inc., Culver City, California, USA) was reacted with 18F-K2.2.2 and K2CO3 in MeCN at 110 °C for 10 min, followed by a deprotection step using 1.0 mol/l HCl at 100 °C for 5 min. [18F]HX4 was purified by RP-HPLC and stabilized with ascorbic acid before sterile filtration. In order to be released, each dose of [18F]HX4 had to have a radiochemical purity greater than 95 %.

Scanners and technical parameters

[18F]HX4 PET/CT scans were performed using a high-resolution full-ring PET/CT scanners, including a GE Discovery, GE Discovery LS, Philips Gemini, and a Siemens Biograph PET/CT scanner. Images were reconstructed using scanner-specific parameters in accordance with each facility’s standard procedure, including at least attenuation and scatter correction. Repeat scans were performed on the same PET/CT scanner using the same protocol and patient positioning without respiratory gating.

[18F]HX4 PET/CT imaging

For each [18F]HX4 PET/CT scan, the patient received a single intravenous bolus injection of 368±48 MBq (range 199–488 MBq) of [18F]HX4 followed by a saline flush. A static PET/CT scan was acquired with an acquisition time of 3 min (range 1.7–5 min) per bed position after an uptake time of 99±10 min (range 89–125 min). The average difference in uptake time between repeat PET scans was 6±7 min (range 0–27 min).

Image evaluation of [18F]HX4

[18F]HX4 PET/CT scans were analyzed using an Inveon Research Workplace (Edition 4.0.0.3; Siemens, Germany). Gross tumor volumes (GTV) of the primary lesion or largest lymph node were defined in centimeters cubed by manual contouring of the tumor on the CT images by one observer (D.C.). These tumor delineations were applied to the PET images and the maximal and mean standardized uptake values (SUVmax, SUVmean) were measured in grams per milliliter. Under the assumption of water density, the SUV is reported as unitless. Background ratios (TBR) were calculated by dividing tumor SUVmax and tumor SUVmean by muscle SUVmean (M)

\[
\text{TBR}_{\text{max}} = \frac{\text{Tumor} \text{ SUV}_{\text{max}}}{M}
\]

\[
\text{TBR}_{\text{mean}} = \frac{\text{Tumor} \text{ SUV}_{\text{mean}}}{M}
\]
The hypoxic volume (HV; in centimeters cubed) of each tumor was defined as the $[^{18}F]HX4$ tumor volume with a TBR $>1.2$ (HV1.2) or TBR $>1.4$ (HV1.4):

$$HV_{1.2} = \text{Volume within GTV with TBR} > 1.2$$
$$HV_{1.4} = \text{Volume within GTV with TBR} > 1.4$$

The fraction of HV (FHV, percent) of each tumor was determined by dividing the HV by its respective GTV:

$$FHV_{1.2} = \frac{HV_{1.2}}{\text{GTV}}$$
$$FHV_{1.4} = \frac{HV_{1.4}}{\text{GTV}}$$

To evaluate the repeatability of the heterogeneous uptake pattern, the second $[^{18}F]HX4$ PET/CT scans were rigidly registered and inspected for accurate registration, and a voxel-wise comparison of the SUVs within the GTV was performed.

### Statistics

For all parameters, the mean±SD are reported. The relationships among GTV-based parameters ($\text{SUV}_{\text{mean}}, \text{SUV}_{\text{max}}, \text{TBR}, \text{HV}, \text{FHV}$) extracted from repeat $[^{18}F]HX4$ PET images were analyzed by calculating Pearson correlation coefficients. A $p$ value $<0.05$ was assumed to be statistically significant. In addition, a Bland-Altman analysis was performed for all parameters providing the mean difference of each parameter and the absolute and relative coefficients of repeatability (CR 1.96 × SD), defined as the value below which the difference between two measurements will be with 95% probability. To evaluate the voxel-wise analysis, a linear fit of the data was performed, providing the correlation coefficient and slope. A Bland-Altman plot was created providing the difference in uptake for each matching voxel ($\Delta$SUV) with the lower and upper limits of agreement of the 95% confidence interval. In addition a histogram of SUVs within the GTV was prepared.

### Results

$[^{18}F]HX4$ PET/CT imaging in nine patients with lung cancer and ten with H&N cancer were included in the analysis. Two sequential baseline $[^{18}F]HX4$ PET/CT scans were performed at an average interval of 1.1 days (range 1–2 days) in patients with lung cancer and 2.1 days (range 1–6 days) in patients with H&N cancer.

$[^{18}F]HX4$ uptake varied considerably among tumors on both the first scan with an average SUV$_{\text{max}}$ of 1.86±0.52 (range...
1.2 – 2.9) and SUV_{mean} of 1.20±0.28 (range 0.85 – 1.90) and the second scan with an average SUV_{max} of 1.84±0.50 (range 1.15 – 2.82) and SUV_{mean} of 1.20±0.28 (range 0.92 – 1.97; Table 2).

The uptake parameters from the first and second scans were highly correlated: \( r = 0.958 \) for SUV_{max} (\( p < 0.001 \), Fig. 1), and \( r = 0.946 \) for SUV_{mean} (\( p < 0.001 \), Supplementary figure). High correlations between scans were also seen within each subgroup of cancer patients: \( r = 0.972 \) for SUV_{max} (\( p < 0.001 \)) and \( r = 0.960 \) for SUV_{mean} (\( p < 0.001 \)) in those with lung cancer, and \( r = 0.945 \) for SUV_{max} (\( p < 0.001 \)) and \( r = 0.952 \) for SUV_{mean} (\( p < 0.001 \)) in those with H\&N cancer. In the Bland-Altman analysis, SUV_{max} showed a mean difference of 0.02 with an absolute CR of 0.29 and a repeatability percentage of 17 % (Fig. 1), and SUV_{mean} showed a mean difference of 0.01 with an absolute CR of 0.18 and a repeatability percentage of 15 %.

High correlations were also seen for TBR_{max} (\( r = 0.962 \), \( p < 0.001 \); Fig. 1) and TBR_{mean} (\( r = 0.965 \), \( p < 0.001 \)). High correlations were also seen within each subgroup of cancer patients: \( r = 0.939 \) for TBR_{max} (\( p < 0.001 \)) and \( r = 0.972 \) for TBR_{mean} (\( p < 0.001 \)) in those with lung cancer, and similarly \( r = 0.972 \) for TBR_{max} (\( p < 0.001 \)) and \( r = 0.964 \) for TBR_{mean} (\( p < 0.001 \)) in those with H\&N cancer. In the Bland-Altman analysis, TBR_{max} showed a mean difference of –0.01 with an absolute CR of 0.30 and a repeatability percentage of 17 % (Fig. 1), and TBR_{mean} showed a mean difference of –0.01 with an absolute CR of 0.11 and a repeatability percentage of 10 %.

**HV and FHV analysis**

The average tumor volume was 70 cm³ (range 2.6 – 361 cm³). The average HV\(_{1.2}\) in the first scan was 32 cm³ (range 0 – 211 cm³) and in the second scan was 34 cm³ (range 0 – 204 cm³; Table 2). For HV\(_{1.2}\), there was a high correlation between the first and second scans (\( r = 0.995 \), \( p < 0.001 \); Supplementary figure) which was retained in each subgroup of cancer patients: \( r = 0.997 \) (\( p < 0.001 \)) in those with lung cancer and \( r = 0.998 \) (\( p < 0.001 \)) in those with H\&N cancer. In the Bland-Altman analysis, HV\(_{1.2}\) showed a mean difference of –1.55 cm³ with an absolute CR of 13.5 cm³ (Supplementary figure).

Applying the higher threshold of 1.4 times the background, in the first scan the average HV\(_{1.4}\) was 19 cm³ (range 0 – 175 cm³) and in the second scan was 19 cm³ (range 0 – 162 cm³; Supplementary table). For HV\(_{1.4}\), there was also a consistently high correlation between the first and second scans (\( r = 0.982 \), \( p < 0.001 \)) which was retained in each subgroup of cancer patients: \( r = 0.959 \) (\( p < 0.001 \)) in those with lung cancer and \( r = 0.999 \) (\( p < 0.001 \)) in those with H\&N cancer. In the Bland-Altman analysis, HV\(_{1.4}\) showed a mean difference of 0.08 cm³ with a confidence interval of –17.2 to 17.4 cm³.

There was a wide range of FHV\(_{1.2}\) due to varying levels of hypoxia among the tumors. In the first scan the average FHV\(_{1.2}\) was 20±25 % (range 0 – 85 %) and in the second scan the average FHV\(_{1.2}\) was 23±26 % (range 0 – 80 %; Table 2). This was also seen when the higher threshold of 1.4 times the background was applied: in the first scan the average FHV\(_{1.4}\) was 9±18 % (range 0 – 71 %) and in the second scan the average FHV\(_{1.4}\) was 10±17 % (range 0 – 63 %; Supplementary table).

For FHV\(_{1.2}\), there was a high correlation between the first and second scans (\( r = 0.957 \), \( p < 0.001 \)) which was retained in each subgroup of cancer patients: \( r = 0.966 \) (\( p < 0.001 \)) in those with lung cancer and \( r = 0.950 \) (\( p < 0.001 \)) in those with H\&N cancer. For FHV\(_{1.4}\), there was also a high correlation between the first and second scans (\( r = 0.975 \), \( p < 0.001 \)) which was retained in each subgroup of cancer patients: \( r = 0.963 \) (\( p < 0.001 \)) in those with lung cancer and \( r = 0.985 \) (\( p < 0.001 \)) in those with H\&N cancer. In the Bland Altman analysis, FHV\(_{1.2}\) showed a mean difference of –3.1 % with an absolute CR of 14.9 %, and FHV\(_{1.4}\) showed a mean difference of –0.9 % and an absolute CR of 7.8 %.

Using 1.2 times the background as the threshold to determine FHV, 79 % of the tumors (15/19) were found to have some level of hypoxia but when the higher threshold of 1.4 times the background was applied to determine FHV, only 47 % of the tumors (9/19) were characterized as having hypoxia.

**Repeatability of the spatial uptake pattern**

An example of voxel-wise image analysis in a patient with head and neck cancer (patient 12) is shown in Fig. 2. Comparison of the heterogeneous uptake within the GTV between the first and second \(^{18}\text{F}\)HX4 PET scans showed a moderate to strong correlation in the majority of patients, with an average correlation coefficient of 0.65±0.14. There were two exceptions (patients 14 and 16) in whom a poor correlation was observed (\( R = 0.38 \) and 0.39). The average slope and intercept of the linear fit of the data were 0.56±0.17 and 0.47±0.19, respectively. The Bland-Altman analysis showed an average ΔSUV of 0.02±0.06, with a lower and upper limit of agreement of 0.15±0.09 and 0.19±0.08. Examples of voxel-wise image analysis in patients with lung cancer (patients 1 and 4) are shown in Fig. 3. In addition, the results for each patient are shown in Table 3.

**Discussion**

The aim of this study was to investigate the repeatability of \(^{18}\text{F}\)HX4 as a noninvasive PET imaging marker for the detection of tumor hypoxia in patients with lung cancer and patients with H\&N cancer. Tumor hypoxia is known to be a
Table 2  Repeatability of $[^{18}F]$HX4 uptake and hypoxic tumor volume and fraction using a threshold of 1.2 times background (HV$_{1.2}$)

| Patient ID | SUV$\text{mean}$ | SUV$\text{max}$ | TBR$\text{max}$ | HV$_{1.2}$ (cm$^3$) | FHV$_{1.2}$ (%) |
|------------|------------------|-----------------|-----------------|---------------------|----------------|
|            | Scan 1 | Scan 2 | Scan 1 | Scan 2 | Scan 1 | Scan 2 | Scan 1 | Scan 2 | Scan 1 | Scan 2 |
| Lung cancer |        |        |        |        |        |        |        |        |        |        |
| 01         | 1.20   | 1.09   | 2.15   | 2.21   | 1.72   | 1.87   | 14.01  | 11.15  | 15.78  | 11.33  |
| 02         | 1.38   | 1.49   | 2.87   | 2.74   | 2.40   | 2.10   | 147.34 | 148.31 | 40.76  | 38.55  |
| 03         | 1.17   | 1.19   | 1.47   | 1.60   | 1.20   | 1.27   | 147.34 | 148.31 | 40.76  | 38.55  |
| 04         | 1.90   | 1.97   | 2.93   | 2.82   | 2.03   | 1.94   | 177.66 | 203.33 | 40.76  | 38.55  |
| 05         | 1.16   | 1.10   | 1.68   | 1.67   | 1.50   | 1.66   | 182.82 | 185.80 | 11.04  | 12.40  |
| 06         | 0.89   | 0.90   | 1.46   | 1.55   | 1.49   | 1.62   | 2.49   | 1.90   | 10.85  | 9.52   |
| 07         | 0.94   | 1.03   | 1.57   | 1.64   | 1.47   | 1.51   | 2.49   | 1.90   | 10.85  | 9.52   |
| 08         | 1.36   | 1.51   | 1.98   | 2.25   | 1.64   | 1.75   | 3.58   | 4.58   | 38.85  | 47.92  |
| 09         | 1.19   | 1.07   | 1.63   | 1.47   | 1.17   | 1.16   | 4.00   | 0.00   | 0.00   | 0.00   |
| Mean±SD   | 1.24±0.29 | 1.26±0.33 | 1.97±0.57 | 1.99±0.53 | 1.63±0.39 | 1.65±0.31 | 40.5±69.9 | 43.3±76.6 | 22.6±23.4 | 26.4±24.6 |
| Head and neck cancer |        |        |        |        |        |        |        |        |        |        |
| 10         | 0.91   | 0.92   | 1.25   | 1.29   | 1.04   | 1.01   | 0.00   | 0.00   | 0.00   | 0.00   |
| 11         | 0.89   | 0.99   | 1.23   | 1.31   | 1.04   | 1.08   | 0.00   | 0.00   | 0.00   | 0.00   |
| 12         | 1.85   | 1.72   | 2.52   | 2.39   | 1.32   | 1.27   | 3.90   | 1.54   | 4.89   | 2.02   |
| 13         | 1.09   | 0.97   | 1.30   | 1.15   | 1.17   | 1.09   | 0.00   | 0.00   | 0.00   | 0.00   |
| 14         | 1.15   | 0.99   | 1.71   | 1.37   | 1.42   | 1.28   | 0.90   | 0.13   | 5.04   | 0.67   |
| 15         | 1.17   | 1.12   | 1.72   | 1.80   | 1.44   | 1.69   | 3.65   | 5.57   | 11.56  | 20.57  |
| 16         | 0.98   | 1.05   | 1.77   | 1.96   | 1.79   | 2.08   | 1.01   | 2.03   | 14.55  | 33.83  |
| 17         | 1.23   | 1.17   | 2.48   | 2.33   | 3.35   | 3.15   | 211.24 | 203.71 | 85.14  | 80.03  |
| 18         | 1.15   | 1.18   | 1.49   | 1.39   | 1.36   | 1.23   | 0.60   | 0.27   | 11.33  | 5.11   |
| 19         | 1.26   | 1.28   | 2.12   | 2.05   | 1.96   | 1.99   | 28.73  | 41.24  | 42.07  | 57.56  |
| Mean±SD   | 1.17±0.27 | 1.14±0.23 | 1.76±0.48 | 1.70±0.46 | 1.59±0.69 | 1.59±0.67 | 25.0±66.0 | 25.5±63.9 | 17.5±26.9 | 20.0±28.5 |
| Mean±SD (total) | 1.20±0.28 | 1.20±0.28 | 1.86±0.52 | 1.84±0.50 | 1.61±0.55 | 1.62±0.52 | 32.3±66.4 | 33.9±68.8 | 19.9±24.7 | 23.0±26.2 |

Fig. 1  Correlation and Bland-Altman plots (including 95% confidence intervals) of the image parameters SUV$\text{max}$ and TBR$\text{max}$.
Dynamic process characterized by the presence of acute and chronic hypoxia. Acute hypoxia is usually the result of a blockage or disruption in the perfusion of the tumor, while chronic hypoxia is mainly caused by limitations of oxygen diffusion due to an inefficient blood vessel network which results in larger distances between the blood vessels and tumor tissue. Static PET imaging will show only the hypoxic status at one specific time-point and contain information about both acute and chronic hypoxia. To be able to select patients for treatment with antihypoxia therapy and/or for a hypoxia-based radiotherapy dose redistribution, it is important to gain an insight into the day-to-day variability in tumor hypoxia and its spatial location. Therefore we compared $^{18}$FHX4 uptake, tumor-to-muscle levels and hypoxic fractions between two consecutive $^{18}$FHX4 PET scans. To obtain information about the spatial distribution of tumor hypoxia, a voxel-wise comparison of the $^{18}$FHX4 uptake was performed.

While there was, as anticipated, a large interpatient variability in $^{18}$FHX4 uptake, no major differences were observed between patients with H&N or patients with lung cancer. The average SUV of $^{18}$FHX4 was identical for lung cancer (1.2±0.3) and H&N cancer lesions (1.2±0.3). There is no standardized method to define tumor hypoxia on PET images. The threshold value for defining tumor hypoxia is dependent on the tracer, tracer pharmacokinetics, and other imaging parameters [16]. In a previous study [16], we showed that PET imaging using a threshold of 1.2 times background at 2 h after injection provides a similar FHV and hypoxic lesion detection rate to imaging using a threshold of 1.4 times background at 4 h after injection. In the current analysis, we included both thresholds to quantify the HV. First we defined the threshold as an uptake above 1.2 times the background level. In this case 89 % (8/9) of the patients with lung cancer and 70 % (7/10) of those with H&N cancer had a hypoxic tumor volume. These percentages are in agreement with previously published results showing, for example, hypoxia in 72 % of patients with non-small-cell lung cancer [16] and in 84 % of those with H&N cancer [17]. Increasing the threshold to 1.4 times background level resulted in decreases in the proportions of hypoxic lesions detected to 67 % of lung cancer lesions (6/9) and 30 % of H&N cancer lesions (3/10).

At the tumor level we observed a high correlation for the frequently used parameters to quantify tumor hypoxia ($S_{\text{max}}$, $S_{\text{mean}}$, TBR, HV, and FHV). This is in agreement with...
with the results of a study by Okamoto et al. [18] who evaluated the reproducibility of the hypoxia PET tracer [18F]FMISO in patients with H&N cancer. They found a high correlation for SUV_{max}, TBR and HV. However, these results do not agree with the previous results of Nehmeh et al. [19] who found a considerable variability in intratumoral uptake between repeat [18F]FMISO PET scans. The reproducibility of the hypoxia PET tracer [18F]FAZA was evaluated by Busk et al. [20] in a mouse model and showed good reproducibility. In comparison to [18F]FDG PET/CT imaging, our observed repeatability percentages (SUV_{max} 17 % and SUV_{mean} 15 %) are smaller than the relative differences required to exceed test–retest variability, which should be larger than 25 % for SUV_{max} and 20 % for SUV_{mean} [21]. Since [18F]HX4 has a lower uptake than [18F]FDG, results from comparisons of the two tracers should be interpreted with caution. However, comparing our relative coefficients of repeatability with the results of the low uptake [18F]FDG measurements (Fig. 1c of de Langen et al. [21]), the observed [18F]HX4 repeatability percentage of the SUV_{max} (17 %) is much lower than expected based on [18F]FDG (approximately 35 %). This high repeatability of [18F]HX4 PET imaging parameters at the tumor level provides confidence that hypoxia PET imaging using [18F]HX4 can be used to reliably detect and quantify tumor hypoxia. This is essential for the use of hypoxia PET imaging as a predictor of treatment response or for monitoring changes in hypoxia during treatment. The detection of hypoxia using [18F]HX4 PET/CT at the tumor level could therefore be used to identify patients who might benefit from hypoxia-targeted treatment [22].

To evaluate the stability of the heterogeneous uptake pattern of [18F]HX4, a voxel-wise comparison was performed. This analysis showed reproducible results (R>0.5) in the majority (17 out of 19) patients with lung cancer or H&N cancer. The observed repeatability is in agreement with previous results of Peeters et al. [23] showing high repeatability of [18F]HX4 uptake in a rat rhabdomyosarcoma model. Repeatability studies using the alternative hypoxia tracer [18F]FMISO have shown contradictory results: Okamoto et al. [18] and Bittner et al. [24] found good repeatability, while Nehmeh et al. [19] observed variability in spatial uptake. For the hypoxia tracer [18F]FAZA, repeated PET/CT imaging was performed during the course of radiotherapy. While Mortensen et al. [25] found a stable location of the HV during treatment, Servagi-Vernat et al. [26] found a spatial move in the HV. The spatial reproducibility of tumor hypoxia, as measured by a hypoxia PET tracer is essential for hypoxia PET-based radiotherapy planning. Three-dimensional information on the hypoxic areas within the tumor can be used to tailor radiotherapy treatment to give a higher radiation dose to hypoxic subvolumes [27]. In this study, [18F]HX4 PET/CT imaging was able to identify stable hypoxic areas in the majority of patients. Therefore, this imaging technique could potentially enable the reliable treatment of hypoxic areas with an
increased radiotherapy dose. Several studies have already shown that it is feasible to perform radiotherapy dose planning based on hypoxia PET images [12, 28, 29].

There were some limitations to this study. First, patients with very heterogeneous disease were included. These tumors have a different histology and might therefore express a different phenotype regarding acute versus chronic tumor hypoxia, which could possibly affect the reproducibility of tracer uptake. Nevertheless, even in this heterogeneous population, a high repeatability in $[^{18}\text{F}]\text{HX4 PET/CT}$ uptake was observed. Second, the study design was multicentric; therefore different PET/CT scanners were used with different physical characteristics and different acquisition protocols. Differences in resolution among the scanners might have led to differences in the tumor hypoxia detection rates. In general, we expect with all scanners a partial volume effect, and particularly in small lesions, in lesions with low uptake and with a small HV this would cause larger differences in absolute uptake measurements. Also, breathing motion in the patients with lung cancer could have caused blurring of the PET signal. The differences in acquisition protocol, i.e., acquisition time per bed position and uptake period, will lead to differences in the observed signal-to-noise ratios, and TBR and SUV measurements [16, 30]. Nevertheless, since we used each patient as his or her own control, the partial volume effect and the effect of different scanners should have had only a minor influence on the repeatability results. Third, the $[^{18}\text{F}]\text{HX4 PET scans}$ were on average acquired at 99 min after injection, with a maximal difference in the time from injection to acquisition of 27 min. Studies reported after this study was completed have shown that the contrast between tumor and background increases up to 4 h after injection. Therefore, the image contrast might have been suboptimal and the differences in uptake parameters observed might have been due to differences in the time from injection to acquisition [30].

In conclusion, repeated PET imaging with the hypoxia tracer $[^{18}\text{F}]\text{HX4}$ provides reliable and reproducible results regarding the (spatial) uptake in patients with head and neck and lung cancer. $[^{18}\text{F}]\text{HX4}$ has the potential to quantify hypoxia in tumors and aid hypoxia-targeted treatments.

| Table 3 Results of the voxel-wise analysis |
|--------------------------------------------|
| Patient ID | Correlation plot | Bland-Altman analysis | |
|            | Pearson’s correlation coefficient ($R$) | Slope | Intercept | Mean $\Delta$SUV | 95% confidence interval |
|            | | | | Lower limit of agreement | Upper limit of agreement |
| Lung cancer | | | | | |
| 01 | 0.51 | 0.39 | 0.64 | 0.05 | −0.21 | 0.30 |
| 02 | 0.61 | 0.46 | 0.85 | −0.06 | −0.34 | 0.23 |
| 03 | 0.69 | 0.72 | 0.35 | −0.01 | −0.15 | 0.13 |
| 04 | 0.85 | 0.82 | 0.4 | −0.03 | −0.20 | 0.14 |
| 05 | 0.58 | 0.78 | 0.02 | 0.12 | −0.10 | 0.35 |
| 06 | 0.83 | 0.63 | 0.27 | 0.03 | −0.10 | 0.15 |
| 07 | 0.55 | 0.45 | 0.62 | −0.05 | −0.24 | 0.13 |
| 08 | 0.82 | 0.86 | 0.28 | −0.04 | −0.21 | 0.13 |
| 09 | 0.62 | 0.44 | 0.52 | 0.07 | −0.07 | 0.21 |
| Mean±SD | 0.67±0.13 | 0.63±0.18 | 0.42±0.24 | 0.02±0.07 | −0.19±0.08 | 0.22±0.12 |
| Head and neck cancer | | | | | |
| 10 | 0.63 | 0.59 | 0.35 | 0.01 | −0.12 | 0.14 |
| 11 | 0.84 | 0.71 | 0.31 | −0.02 | −0.12 | 0.07 |
| 12 | 0.86 | 0.70 | 0.45 | 0.05 | −0.09 | 0.19 |
| 13 | 0.69 | 0.30 | 0.45 | 0.15 | 0.06 | 0.25 |
| 14 | 0.38 | 0.28 | 0.61 | 0.11 | −0.07 | 0.28 |
| 15 | 0.56 | 0.49 | 0.52 | 0.04 | −0.12 | 0.20 |
| 16 | 0.39 | 0.37 | 0.68 | −0.03 | −0.25 | 0.19 |
| 17 | 0.63 | 0.61 | 0.42 | 0.03 | −0.23 | 0.30 |
| 18 | 0.70 | 0.49 | 0.61 | −0.01 | −0.11 | 0.09 |
| 19 | 0.63 | 0.49 | 0.64 | 0.00 | −0.21 | 0.21 |
| Mean±SD | 0.63±0.16 | 0.50±0.15 | 0.50±0.13 | 0.03±0.06 | −0.13±0.09 | 0.19±0.07 |
| Mean±SD (total) | 0.65±0.14 | 0.56±0.17 | 0.46±0.19 | 0.03±0.06 | −0.16±0.09 | 0.21±0.10 |
Compliance with ethical standards

Conflicts of interest  K. Szardenings is an employee of Threshold Pharmaceuticals, the company that owns and develops [18F]HX4.

Ethical approval  All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not describe any studies with animals performed by any of the authors.

Informed consent  Informed consent was obtained from all individual participants included in the study.

Acknowledgments  Authors acknowledge financial support from the Dutch technology Foundation STW (grant no. 10690 DuCAT), which is the applied science division of NWO, and the Technology Programme of the Ministry of Economic Affairs. Authors also acknowledge financial support from EU 7th framework program (ARTFORCE - n° 257144), Kankeronderzoekfonds Limburg from the Health Foundation Limburg and the Dutch Cancer Society (KWF UM 2011-5020, KWF MAC 2013-6425).

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011;108(35):14620–5. doi:10.1073/pnas.1102526108.
2. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO. Nucl Med Commun. 2012;33(10):1096–102. doi:10.1097/NM.0b013e3283571016.
3. Wouters BG, van den Beucken T, Magagnin MG, Lambin P, Koumenis C. Targeting hypoxia tolerance in cancer. Drug Resist Updat. 2004;7(1):25–40. doi:10.1016/j.drup.2003.12.004.
4. Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21(10):1516–54. doi:10.1089/ars.2013.5378.
5. Wouters BG, Kortitzinsky M, Chiu RK, Thys J, Buijsen J, Lambin P. Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol. 2003;13(1):31–41. doi:10.1053/srao.2003.50004.
6. Nordmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57(1):39–43.
7. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 2007;68(1):291–300. doi:10.1016/j.ijrobp.2006.11.061.
8. Sun JD, Liu Q, Wang J, Aлуswalid J, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res. 2012;18(3):758–70. doi:10.1158/1078-0432.CCR-11-1980.
9. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393–410. doi:10.1038/nrc3064.
10. Rami M, Dubois L, Parvathaneni NK, Alterio V, van Kuijk SJ, Monti SM, et al. Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J Med Chem. 2013;56(21):8512–20. doi:10.1021/jm4009532.
11. Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, Saraya R, et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol. 2013;108(3):523–8. doi:10.1016/j.radonc.2013.06.018.
12. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol. 2010;97(2):172–5. doi:10.1016/j.radonc.2010.05.012.
13. Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology – multifactorial decision support systems. Nat Rev Clin Oncol. 2013;10(1):27–40. doi:10.1038/nrclinonc.2012.196.
14. van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010;37(9):1663–8. doi:10.1007/s00259-010-1437-x.
15. Doss M, Zhang JJ, Belanger MJ, Stubbs JB, Hostetler ED, Alpaugh K, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010;31(12):1016–24. doi:10.1097/NM.0b013e3283407950.
16. Zegers CM, van Elmpft W, Wierts R, Reyemmen B, Sharifi H, Ollers MC, et al. Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol. 2013;109(1):58–64. doi:10.1016/j.radonc.2013.08.031.
17. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol. 2012;105(1):21–8. doi:10.1016/j.radonc.2012.08.019.
18. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013;54(2):201–7. doi:10.2967/jnumed.112.109330.
19. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):235–42. doi:10.1016/j.ijrobp.2007.08.036.
20. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KY, et al. PET imaging with FAXA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging. 2013;40(2):186–97. doi:10.1007/s00259-012-2258-x.
21. de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, et al. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med. 2012;53(5):701–8. doi:10.2967/jnumed.111.095299.
22. Peeters SG, Zegers CM, Yaromina A, van Elmpft W, Dubois L, Lambin P. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Q J Nucl Med Mol Imaging. 2015;59(1):39–57.
23. Peeters SG, Zegers CM, Lieuwes NG, van Elmpft W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [18F]HX4, [18F]FAXA, and [18F]FMISO in a preclinical
tumor model. Int J Radiat Oncol Biol Phys. 2015;91(2):351–9. doi: 10.1016/j.ijrobp.2014.09.045.

24. Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA, et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol. 2013;108(3):511–6. doi:10.1016/j.radonc.2013.06.012.

25. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105(1):14–20. doi:10.1016/j.radonc.2012.09.015.

26. Servagi-Vernat S, Differding S, Hanin FX, Labar D, Bol A, Lee JA, et al. A prospective clinical study of 18F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging. 2014;41(8):1544–52. doi:10.1007/s00259-014-2730-x.

27. Zegers CM, van Elmpt W, Reyment B, Even AJ, Troost EG, Ollers MC, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res. 2014;20(24):6389–97. doi:10.1158/1078-0432.CCR-14-1524.

28. Petit SF, Dekker AL, Seigneuric R, Murrer L, van Riel NA, Nordsmark M, et al. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol. 2009;54(7):2179–96. doi:10.1088/0031-9155/54/7/022.

29. Clausen MM, Hansen AE, Af Rosenschold PM, Kjaer A, Kristensen AT, McEvoy FJ, et al. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiat Oncol. 2013;8:262. doi:10.1186/1748-717X-8-262.

30. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50 Suppl 1:11S–20. doi:10.2967/jnumed.108.057182.

31. Verwer EE, van Velden FH, Bahce I, Yaqub M, Schuit RC, Windhorst AD, et al. Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(10):1523–31. doi:10.1007/s00259-013-2462-3.